Novo Nordisk has front-loaded DKK 1 billion of restructuring costs into its third quarter, effectively reserving those savings to bolster Q4 results. With operating expenses now lower and cost synergies set to accrue, consensus forecasts for the fourth quarter have been conservative, leaving room for a potential earnings beat. Analysts note that the company’s margin profile should improve sequentially, driven by the timing of these cost reductions and stable gross margin trends above 80%, setting the stage for a stronger finish to 2025 than the market currently expects.

In January 2026, Novo Nordisk launched the FDA-approved oral version of its flagship weight-management therapy, Wegovy. During the debut week, pharmacies filled over 18,000 prescriptions, signaling robust demand in what the company estimates to be an addressable market of roughly 85 million U.S. adults with obesity or overweight. Early uptake has been strongest in metropolitan regions with established obesity management programs, and payor coverage agreements signed with three major insurers cover more than 60% of eligible patients, laying the groundwork for sustained volume growth through the year.

To support surging demand for its GLP-1 franchise, Novo Nordisk is on track to double U.S. fill-finish capacity by mid-2026 through integration of Catalent’s site in St. Petersburg, Florida. This expansion will alleviate previous bottlenecks that led to shipment delays and inventory drawdowns. At the same time, price competition from rival therapies and telehealth providers has intensified; the company’s updated guidance factors in slower growth rates for both Ozempic and Wegovy injectables. Management believes that enhanced manufacturing scale, combined with differentiated oral delivery, will sustain market share and protect long-term margin expansion despite the more contested competitive landscape.